SHANGHAI/SUZHOU, China, April 19 (Reuters) - China's vaccine developers stuck with unused mRNA COVID shots and idle manufacturing plants are pursuing new targets for the novel messenger RNA technology, but they face a tough path, crimped by a lack of revenue.
June 29 (Reuters) - Chinese drug maker CSPC Pharmaceutical Group (1093.HK) said on Thursday it signed a strategic partnership with Pfizer (PFE.N) to launch a local brand of an oral COVID-19 treatment, in an attempt to improve the access for treatment in China.
Elevation Oncology Highlights Clinical Data for SYSA1801 (EO-3021) to be Presented by Partner CSPC Pharmaceutical Group Limited at ASCO 2023
China has approved its first domestically developed mRNA vaccine against COVID-19, CSPC Pharmaceutical Group Ltd said on Wednesday, a major achievement in a country that has declined to use Western COVID shots to support domestic research.
SEOUL, South Korea, Oct. 11, 2022 /PRNewswire/ -- HanAll Biopharma (KRX: 009420.KS), a global biopharmaceutical company developing innovative medicines, today announced that its licensed partner in greater China, Harbour BioMed, has signed an exclusive sublicense agreement with CSPC NBP Pharmaceutical Co., Ltd. (NBP Pharma), a wholly-owned subsidiary of CSPC, a RBM 28 billion 2021 sales company based in China, for HanAll's FcRn inhibitor batoclimab. The deal grants NBP Pharma the exclusive rights to develop and commercialize batoclimab in Greater China including mainland of China, Hong Kong, Macau, and Taiwan. Under the agreement Harbour BioMed will receive a total of over RMB 1 billion, including the RMB 150 million worth upfront payment along with the potential milestone payments.
Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision oncology products for...
SUZHOU, China, Jan. 5, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK) jointly announced that the IND application for the pivotal clinical trial (KN026-CSP-001) of the anti-HER2 bispecific antibody KN026 combined with chemotherapy was approved by the Center for Drug Evaluation (CDE) of NMPA.
CSPC Ouyi Pharmaceutical `s Generic Carbamazepine Receives Approval in US
CSPC OUYI's Generic Esomeprazole Magnesium Receives Approval In US